- Home
- XPL vs ANL Comparison
XPL vs ANL Comparison
Compare XPL & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPL
- ANL
- Stock Information
- Founded
- XPL 1984
- ANL 2004
- Country
- XPL United States
- ANL Cayman Islands
- Employees
- XPL N/A
- ANL N/A
- Industry
- XPL Precious Metals
- ANL
- Sector
- XPL Basic Materials
- ANL
- Exchange
- XPL Nasdaq
- ANL Nasdaq
- Market Cap
- XPL 62.5M
- ANL 61.8M
- IPO Year
- XPL N/A
- ANL 2023
- Fundamental
- Price
- XPL $0.78
- ANL $1.67
- Analyst Decision
- XPL Strong Buy
- ANL Hold
- Analyst Count
- XPL 2
- ANL 1
- Target Price
- XPL $1.20
- ANL N/A
- AVG Volume (30 Days)
- XPL 605.8K
- ANL 7.1K
- Earning Date
- XPL 11-07-2025
- ANL 11-04-2025
- Dividend Yield
- XPL N/A
- ANL N/A
- EPS Growth
- XPL N/A
- ANL N/A
- EPS
- XPL N/A
- ANL N/A
- Revenue
- XPL N/A
- ANL N/A
- Revenue This Year
- XPL N/A
- ANL N/A
- Revenue Next Year
- XPL N/A
- ANL N/A
- P/E Ratio
- XPL N/A
- ANL N/A
- Revenue Growth
- XPL N/A
- ANL N/A
- 52 Week Low
- XPL $0.54
- ANL $1.10
- 52 Week High
- XPL $0.90
- ANL $3.89
- Technical
- Relative Strength Index (RSI)
- XPL 55.19
- ANL 47.91
- Support Level
- XPL $0.68
- ANL $1.55
- Resistance Level
- XPL $0.86
- ANL $1.73
- Average True Range (ATR)
- XPL 0.07
- ANL 0.08
- MACD
- XPL 0.01
- ANL -0.00
- Stochastic Oscillator
- XPL 55.80
- ANL 48.00
About XPL Solitario Resources Corp.
Solitario Resources Corp is exploration company engaging in acquiring, exploring, and developing zinc properties and other precious metals in safe jurisdictions in North and South America. It has joint venture interests in large, high-grade zinc development projects. The Florida Canyon Zinc Project in Peru is a development asset held jointly with Nexa Resources S.A., Golden Crest Project in South Dakota and the Lik Zinc Project represents a large-tonnage, high-grade development project in Alaska in partnership with Teck Resources. In addition, the company has an additional portfolio of exploration properties and royalties in the Americas.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.